<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="83a474ed-d005-435f-8ff9-415d4a53ffd6"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>
      <content styleCode="bold">5% Dextrose and Electrolyte No. 48 Injection </content>
      <br/>
      <content styleCode="bold"> (Multiple Electrolytes and Dextrose Injection, Type 1, USP) </content>
      <br/>
   </title>
   <effectiveTime value="20200213"/>
   <setId root="b283a454-0c20-4fbf-92d3-dae1f3cd3cad"/>
   <versionNumber value="14"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="005083209" root="1.3.6.1.4.1.519.1"/>
            <name>Baxter Healthcare Company</name>
            <assignedEntity>
               <assignedOrganization>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="059140764" root="1.3.6.1.4.1.519.1"/>
                        <name>Baxter Healthcare Corporation</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0338-0143" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0338-0143" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84732" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="LABEL"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0338-0143" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACK"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0338-0143" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84382" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="STERILIZE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0338-0143" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C82401" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="API MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0338-0143" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="194684502" root="1.3.6.1.4.1.519.1"/>
                        <name>Baxter Healthcare Corporation</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0338-0143" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="d40e382f-637f-4bc2-b2d8-9645dea22e95"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20170828"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0338-0143" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Dextrose and Electrolyte No. 48</name>
                        <formCode code="C42946" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Sodium Lactate, Potassium Chloride, Magnesium Chloride, Monobasic Potassium Phosphate, Sodium Chloride and Dextrose monohydrate</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="g" value="5"/>
                              <denominator unit="mL" value="100"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="LX22YL083G" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>DEXTROSE MONOHYDRATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="5SL0G7R0OK" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>ANHYDROUS DEXTROSE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="260"/>
                              <denominator unit="mL" value="100"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="TU7HW0W0QT" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM LACTATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="33X04XA5AT" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>LACTIC ACID</name>
                                 </activeMoiety>
                              </activeMoiety>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="LYR4M0NH37" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>SODIUM CATION</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="141"/>
                              <denominator unit="mL" value="100"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="660YQ98I10" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POTASSIUM CHLORIDE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="295O53K152" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>POTASSIUM CATION</name>
                                 </activeMoiety>
                              </activeMoiety>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="Q32ZN48698" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>CHLORIDE ION</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="31"/>
                              <denominator unit="mL" value="100"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="02F3473H9O" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM CHLORIDE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="Q32ZN48698" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>CHLORIDE ION</name>
                                 </activeMoiety>
                              </activeMoiety>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="T6V3LHY838" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>MAGNESIUM CATION</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="20"/>
                              <denominator unit="mL" value="100"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="4J9FJ0HL51" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POTASSIUM PHOSPHATE, MONOBASIC</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="NK08V8K8HR" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>PHOSPHATE ION</name>
                                 </activeMoiety>
                              </activeMoiety>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="295O53K152" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>POTASSIUM CATION</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="12"/>
                              <denominator unit="mL" value="100"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="451W47IQ8X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM CHLORIDE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="LYR4M0NH37" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>SODIUM CATION</name>
                                 </activeMoiety>
                              </activeMoiety>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="Q32ZN48698" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>CHLORIDE ION</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="500"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="0338-0143-03" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43167" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BAG"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="19790202"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA017484" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="19790202"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38276" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAVENOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="i4i_section_id_inv-eb42eace-575f-40a2-9ca2-fb520ab72c9b">
               <id root="7121e4b8-dbc3-4260-ac81-eaa48acc2c9e"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <text>
                  <paragraph>in VIAFLEX Plastic Container</paragraph>
               </text>
               <effectiveTime value="20070509"/>
            </section>
         </component>
         <component>
            <section ID="i4i_description_id_inv-3fec0556-a2c1-4bc5-96c0-f85f968ca0cb">
               <id root="ba5dc024-9518-4523-8f5b-95c9de94ef37"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>DESCRIPTION</title>
               <text>
                  <paragraph>5% Dextrose and Electrolyte No. 48 Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) is a sterile, nonpyrogenic solution for fluid and electrolyte replenishment and caloric supply in a single dose container for intravenous administration. Each 100 mL contains 5 g Dextrose Hydrous, USP*, 260 mg Sodium Lactate (C<sub>3</sub>H<sub>5</sub>NaO<sub>3</sub>), 141 mg Potassium Chloride, USP (KCl), 31 mg Magnesium Chloride, USP (MgCl<sub>2</sub>•6H<sub>2</sub>0), 20 mg Monobasic Potassium Phosphate, NF (KH<sub>2</sub>PO<sub>4</sub>), and 12 mg Sodium Chloride, USP (NaCl). It contains no antimicrobial agents. The pH is 5.0 (4.0 to 6.5).</paragraph>
                  <renderMultiMedia ID="id259" referencedObject="nn-wep7c9dd-582f-4ea6-9977-f5793a97abb0"/>
                  <paragraph>5% Dextrose and Electrolyte No. 48 Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) administered intravenously has value as a source of water, electrolytes, and calories.  One liter has an ionic concentration of 25 mEq sodium, 20 mEq potassium, 3 mEq magnesium, 24 mEq chloride, 23 mEq lactate and 3 mEq phosphate (as HPO<sub>4</sub>
                     <sup>2-</sup>).  The osmolarity is 348 mOsmol/L (calc).  Normal physiologic osmolarity range is approximately 280 to 310 mOsmol/L.  Administration of substantially hypertonic solutions (≥ 600 mOsmol/L) may cause vein damage.  The caloric content is 180 kcal/L.</paragraph>
                  <paragraph>Dextrose is derived from corn.</paragraph>
                  <paragraph>The VIAFLEX plastic container is fabricated from a specially formulated polyvinyl chloride (PL 146 Plastic). The amount of water that can permeate from inside the container into the overwrap is insufficient to affect the solution significantly. Solutions in contact with the plastic container can leach out certain of its chemical components in very small amounts within the expiration period, e.g., di-2-ethylhexyl phthalate (DEHP), up to 5 parts per million. However, the safety of the plastic has been confirmed in tests in animals according to USP biological tests for plastic containers as well as by tissue culture toxicity studies.</paragraph>
               </text>
               <effectiveTime value="20200213"/>
               <component>
                  <observationMedia ID="nn-wep7c9dd-582f-4ea6-9977-f5793a97abb0">
                     <text>Structural Formula</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="image-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="i4i_clinical_pharmacology_id_inv-0f0b6183-b2f0-4a61-b24e-c465d34e0066">
               <id root="1705f16a-96c4-4b23-b8a4-1aca6d5282f5"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>CLINICAL PHARMACOLOGY</title>
               <text>
                  <paragraph>5% Dextrose and Electrolyte No. 48 Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) has value as a source of water, electrolytes and calories. They are capable of inducing diuresis depending on the clinical condition of the patient.</paragraph>
                  <paragraph>5% Dextrose and Electrolyte No. 48 Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) produce a metabolic alkalinizing effect. Lactate ions are metabolized ultimately to carbon dioxide and water, which requires the consumption of hydrogen cations.</paragraph>
               </text>
               <effectiveTime value="20070509"/>
            </section>
         </component>
         <component>
            <section ID="i4i_indications_id_inv-d1d1b780-8980-48bf-ae1f-1b1f90ce5533">
               <id root="0cb8b796-f788-4e36-95dd-bba84e3964c6"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>5% Dextrose and Electrolyte No. 48 Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) is indicated as a source of water, electrolytes, and calories or as an alkalinizing agent.</paragraph>
               </text>
               <effectiveTime value="20070509"/>
            </section>
         </component>
         <component>
            <section ID="i4i_contraindications_id_inv-8f6eb5b7-fe06-44df-aac6-af8c378b597a">
               <id root="0ada0a6e-3d75-43f3-b897-33c852371511"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>CONTRAINDICATIONS</title>
               <text>
                  <paragraph>5% Dextrose and Electrolyte No. 48 Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) is contraindicated in patients </paragraph>
                  <list listType="unordered">
                     <item>
                        <caption>•</caption>with a known hypersensitivity to the product (see <content styleCode="bold">
                           <linkHtml href="#i4i_warnings_id_inv-ede11157-af5e-407c-8086-46b984950519">WARNINGS</linkHtml>
                        </content>)</item>
                     <item>
                        <caption>•</caption>with clinically significant hyperglycemia (see <content styleCode="bold">
                           <linkHtml href="#i4i_warnings_id_inv-ede11157-af5e-407c-8086-46b984950519">WARNINGS</linkHtml>)</content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20200213"/>
            </section>
         </component>
         <component>
            <section ID="i4i_warnings_id_inv-ede11157-af5e-407c-8086-46b984950519">
               <id root="c4abcb88-25d9-40b2-945a-a69bc39ee8e1"/>
               <code code="34071-1" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS SECTION"/>
               <title>WARNINGS</title>
               <effectiveTime value="20200213"/>
               <component>
                  <section ID="ID_46232a2e-f78a-46d9-821c-cd540571e8eb">
                     <id root="9ee40714-40b2-469b-a568-7653e82cf0f6"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Hypersensitivity Reactions </title>
                     <text>
                        <paragraph>Hypersensitivity and infusion reactions have been reported with 5% Dextrose and Electrolyte No. 48 Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP). See <linkHtml href="#i4i_adverse_effects_id_inv-06affc8f-d649-475a-9fe6-f9b8229384b5">ADVERSE REACTIONS</linkHtml>.</paragraph>
                        <paragraph>Stop the infusion immediately if signs or symptoms of a hypersensitivity reaction develop, such as tachycardia, chest pain, dyspnea and flushing.  Institute appropriate therapeutic countermeasures as clinically indicated.</paragraph>
                     </text>
                     <effectiveTime value="20200213"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_aed5ce6c-05bd-41c0-b641-04f81643889d">
                     <id root="536ad09c-7665-43ff-a941-2aba0ca99820"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Electrolyte Imbalances </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Fluid Overload</content>
                        </paragraph>
                        <paragraph>Depending on the volume and rate of infusion, the intravenous administration of 5% Dextrose and Electrolyte No. 48 Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) can cause electrolyte disturbances such as overhydration and congested states, including pulmonary congestion and edema. </paragraph>
                        <paragraph>Avoid 5% Dextrose and Electrolyte No. 48 Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) in patients with or at risk for fluid and/or solute overloading.  If use cannot be avoided, monitor fluid balance, electrolyte concentrations, and acid base balance, as needed and especially during prolonged use.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Hyponatremia</content>
                        </paragraph>
                        <paragraph>5% Dextrose and Electrolyte No. 48 Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) may cause hyponatremia. 5% Dextrose and Electrolyte No. 48 Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) is a hypertonic solution. In the body, however, glucose containing fluids can become extremely physiologically hypotonic due to rapid glucose metabolization. Monitoring of serum sodium is particularly important for hypotonic fluids.</paragraph>
                        <paragraph>Hyponatremia can lead to acute hyponatremic encephalopathy characterized by headache, nausea, seizures, lethargy, and vomiting. Patients with brain edema are at particular risk of severe, irreversible and life-threatening brain injury.</paragraph>
                        <paragraph>The risk of hospital-acquired hyponatremia is increased in patients with cardiac or pulmonary failure, and in patients with non-osmotic vasopressin release (including SIADH) treated with high volume of physiologically hypotonic 5% Dextrose and Electrolyte No. 48 Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP).</paragraph>
                        <paragraph>Avoid 5% Dextrose and Electrolyte No. 48 Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) in hypervolemic or overhydrated patients. If use cannot be avoided, monitor serum sodium concentrations.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Hyperglycemia and Hyperosmolar Hyperglycemic State</content>
                        </paragraph>
                        <paragraph>Administration of solutions containing dextrose and lactate in patients with impaired glucose tolerance or diabetes mellitus may worsen hyperglycemia (see <content styleCode="bold">
                              <linkHtml href="#i4i_precautions_id_inv-88d565c8-7a5b-421b-840e-6d8c31542590">PRECAUTIONS</linkHtml>, <linkHtml href="#i4i_pediatric_use_id_inv-a1840d19-c7d2-4def-9d27-9d863ebce4db">Pediatric Use</linkHtml>
                           </content>). Administration of dextrose at a rate exceeding the patient’s utilization rate may lead to hyperglycemia, coma, and death.</paragraph>
                        <paragraph>Hyperglycemia is associated with an increase in serum osmolality, resulting in osmotic diuresis, dehydration and electrolyte losses.</paragraph>
                        <paragraph>Patients with underlying central nervous system disease and renal impairment who receive dextrose infusions, may be at greater risk of developing hyperosmolar hyperglycemic state.</paragraph>
                        <paragraph>Monitor blood glucose concentrations and treat hyperglycemia to maintain concentrations within normal limits while administering 5% Dextrose and Electrolyte No. 48 Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP). Insulin may be administered or adjusted to maintain optimal blood glucose concentrations.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Hypernatremia</content>
                        </paragraph>
                        <paragraph>Hypernatremia may occur with 5% Dextrose and Electrolyte No. 48 Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP).  Conditions that may increase the risk of hypernatremia, fluid overload and edema (central and peripheral), include patients with: primary hyperaldosteronism; secondary hyperaldosteronism associated with, for example, hypertension, congestive heart failure, liver disease (including cirrhosis), renal disease (including renal artery stenosis, nephrosclerosis); and pre-eclampsia.</paragraph>
                        <paragraph>Certain medications, such as corticosteroids or corticotropin, may also increase risk of sodium and fluid retention, see <content styleCode="bold">
                              <linkHtml href="#i4i_precautions_id_inv-88d565c8-7a5b-421b-840e-6d8c31542590">PRECAUTIONS</linkHtml>
                           </content>.</paragraph>
                        <paragraph>Avoid 5% Dextrose and Electrolyte No. 48 Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) in patients with, or at risk for, hypernatremia. If use cannot be avoided, monitor serum sodium concentrations.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Hypermagnesemia</content>
                        </paragraph>
                        <paragraph>Avoid solutions containing magnesium, including 5% Dextrose and Electrolyte No. 48 Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) in patients with or predisposed to hypermagnesemia, including patients with severe renal impairment and those patients receiving magnesium therapy (e.g., treatment of eclampsia and myasthenia gravis). </paragraph>
                        <paragraph>5% Dextrose and Electrolyte No. 48 Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) is not indicated for the treatment of hypomagnesemia. </paragraph>
                        <paragraph>
                           <content styleCode="underline">Acidosis</content>
                        </paragraph>
                        <paragraph>5% Dextrose and Electrolyte No. 48 Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) is not for use for the treatment of lactic acidosis or severe metabolic acidosis in patients with severe liver and/or renal impairment.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Alkalosis</content>
                        </paragraph>
                        <paragraph>Excess administration of 5% Dextrose and Electrolyte No. 48 Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) can result in metabolic alkalosis. Avoid 5% Dextrose and Electrolyte No. 48 Injection (Multiple Electrolytes Injection, Type 1, USP) in patients with alkalosis or at risk for alkalosis. </paragraph>
                        <paragraph>5% Dextrose and Electrolyte No. 48 Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) is not indicated for the treatment of hypochloremic hypokalemic alkalosis.  Avoid use in patients with hypochloremic hypokalemic alkalosis. </paragraph>
                        <paragraph>
                           <content styleCode="underline">Hypocalcemia</content>
                        </paragraph>
                        <paragraph>5% Dextrose and Electrolyte No. 48 Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) contains no calcium, and an increase in plasma pH due to its alkalinizing effect may lower the concentration of ionized (not-protein bound) calcium. Avoid 5% Dextrose and Electrolyte No. 48 Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) in patients with hypocalcemia.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Hyperkalemia</content>
                        </paragraph>
                        <paragraph>Potassium-containing solutions, including 5% Dextrose and Electrolyte No. 48 Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) may increase the risk of hyperkalemia. </paragraph>
                        <paragraph>Patient’s at increased risk of developing hyperkalemia include those:</paragraph>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>With conditions predisposing to hyperkalemia and/or associated with increased sensitivity to potassium, such as patients with severe renal impairment, acute dehydration, extensive tissue injury or burns, certain cardiac disorders such as congestive heart failure.</item>
                           <item>
                              <caption>•</caption>Treated concurrently or recently with agents or products that cause or increase the risk of hyperkalemia (see <content styleCode="bold">
                                 <linkHtml href="#i4i_precautions_id_inv-88d565c8-7a5b-421b-840e-6d8c31542590">PRECAUTIONS</linkHtml>
                              </content>). </item>
                        </list>
                        <paragraph>Avoid 5% Dextrose and Electrolyte No. 48 Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) in patients with, or at risk for hyperkalemia. If use cannot be avoided, monitor serum potassium concentrations.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Hyperphosphatemia</content>
                        </paragraph>
                        <paragraph>5% Dextrose and Electrolyte No. 48 Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) may increase the risk of hyperphosphatemia.  Avoid use in patients with hyperphosphatemia or conditions predisposing to hyperphosphatemia, such as patients with severe renal or adrenal impairment.</paragraph>
                     </text>
                     <effectiveTime value="20200213"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="i4i_precautions_id_inv-88d565c8-7a5b-421b-840e-6d8c31542590">
               <id root="0f42e475-b755-4353-a6f6-30ae51a95ff7"/>
               <code code="42232-9" codeSystem="2.16.840.1.113883.6.1" displayName="PRECAUTIONS SECTION"/>
               <title>PRECAUTIONS</title>
               <text>
                  <paragraph>
                     <content styleCode="underline">Patients with Renal Impairment </content>
                  </paragraph>
                  <paragraph>In patients with renal impairment, administration of 5% Dextrose and Electrolyte No. 48 Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) may result in sodium and/or potassium or magnesium retention (see <content styleCode="bold">
                        <linkHtml href="#i4i_warnings_id_inv-ede11157-af5e-407c-8086-46b984950519">WARNINGS</linkHtml>
                     </content>). Avoid 5% Dextrose and Electrolyte No. 48 Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) in patients with severe renal impairment or conditions that may cause sodium, potassium, magnesium, or phosphate retention, fluid overload, or edema. If use cannot be avoided, monitor patients with severe renal impairment for development of these adverse reactions.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Patients with Hepatic Impairment</content>
                  </paragraph>
                  <paragraph>In patients with severe hepatic impairment, lactate metabolism may be impaired and 5% Dextrose and Electrolyte No. 48 Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) may not produce its alkalinization.  Consider when monitoring serum lactate levels.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Monitoring of Serum Lactate Levels </content>
                  </paragraph>
                  <paragraph>Administration of 5% Dextrose and Electrolyte No. 48 Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) may result in an iatrogenic increase in serum lactate levels in patients with severe metabolic acidosis including lactic.</paragraph>
               </text>
               <effectiveTime value="20200213"/>
               <component>
                  <section ID="ID_24690bb2-f76a-451f-90e3-bab762c87cff">
                     <id root="cec2a8e3-3d79-43bf-acff-d76a7d1f3045"/>
                     <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
                     <title>Drug Interactions </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Other Products that Affect Fluid and/or Electrolyte Balance</content>
                        </paragraph>
                        <paragraph>Administration of 5% Dextrose and Electrolyte No. 48 Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) to patients treated concomitantly with drugs associated with sodium and fluid retention may increase the risk of hypernatremia and volume overload.  Avoid use of 5% Dextrose and Electrolyte No. 48 Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) in patients receiving such products, such as corticosteroids or corticotropin.  If use cannot be avoided, monitor serum electrolytes, fluid balance and acid-base balance. </paragraph>
                        <paragraph>
                           <content styleCode="underline">Other Drugs that Increase the Risk of Hyponatremia</content>
                        </paragraph>
                        <paragraph>Administration of 5% Dextrose and Electrolyte No. 48 Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) in patients treated concomitantly with medications associated with hyponatremia may increase the risk of developing hyponatremia.</paragraph>
                        <paragraph>Avoid use of 5% Dextrose and Electrolyte No. 48 Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) in patients receiving products, such as diuretics, and certain antiepileptic and psychotropic medications. Drugs that increase the vasopressin effect reduce renal electrolyte free water excretion and may also increase the risk of hyponatremia following treatment with intravenous fluids. If use cannot be avoided, monitor serum sodium concentrations.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Other Products that Increase the Risk of Hyperkalemia</content>
                        </paragraph>
                        <paragraph>Because of its potassium content, avoid use of 5% Dextrose and Electrolyte No. 48 Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) in patients receiving products that can cause hyperkalemia or increase the risk of hyperkalemia, such as potassium sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, or the immunosuppressants tacrolimus and cyclosporine. If use cannot be avoided, monitor serum potassium concentrations.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Lithium</content>
                        </paragraph>
                        <paragraph>Renal clearance of lithium may be increased during administration of 5% Dextrose and Electrolyte No. 48 Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP). Monitor serum lithium concentrations during concomitant use. </paragraph>
                        <paragraph>
                           <content styleCode="underline">Drugs with pH Dependent Renal Elimination </content>
                        </paragraph>
                        <paragraph>Due to its alkalinizing effect (formation of bicarbonate), 5% Dextrose and Electrolyte No. 48 Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) may interfere with the elimination of drugs with pH dependent renal elimination. Renal clearance of acidic drugs may be increased.  Renal clearance of alkaline drugs may be decreased.</paragraph>
                     </text>
                     <effectiveTime value="20200213"/>
                  </section>
               </component>
               <component>
                  <section ID="i4i_pregnancy_id_inv-e769b083-0108-484f-8e40-1542734a484a">
                     <id root="e3dd8a5a-0067-4cc2-8928-dded9ebe5f9c"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>Pregnancy</title>
                     <effectiveTime value="20200213"/>
                     <component>
                        <section ID="ID_AE95E73A-5ABB-4D38-AD2E-D1A2E9CF93E7">
                           <id root="922b3bf9-6898-46b6-9aa5-65e0e06536c1"/>
                           <code code="34077-8" codeSystem="2.16.840.1.113883.6.1" displayName="TERATOGENIC EFFECTS SECTION"/>
                           <title>
                              <content styleCode="underline">Teratogenic Effects</content>
                           </title>
                           <text>
                              <paragraph>Animal reproduction studies have not been conducted with 5% Dextrose and Electrolyte No. 48 Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP).  </paragraph>
                              <paragraph>Intrapartum maternal intravenous infusion of glucose-containing solutions may result in fetal insulin production, with an associated risk of fetal hyperglycemia and metabolic acidosis as well as rebound hypoglycemia in the neonate. 5% Dextrose and Electrolyte No. 48 Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) should be given to a pregnant woman by health care providers only after careful consider of the potential risk and benefits for each specific patient.</paragraph>
                           </text>
                           <effectiveTime value="20200213"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="i4i_pediatric_use_id_inv-a1840d19-c7d2-4def-9d27-9d863ebce4db">
                     <id root="b522da25-5f58-48a4-9198-807051d8a770"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>Pediatric Use</title>
                     <text>
                        <paragraph>Safety and effectiveness of 5% Dextrose and Electrolyte No. 48 Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) in pediatric patients have not been established by adequate and well controlled trials. </paragraph>
                        <paragraph>The use of 5% Dextrose and Electrolyte No. 48 Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) in pediatric patients is based on clinical practice (see <content styleCode="bold">
                              <linkHtml href="#i4i_dosage_admin_id_inv-830fb45a-a4d4-4878-833b-3d20831f45fc">DOSAGE AND ADMINISTRATION</linkHtml>
                           </content>).</paragraph>
                        <paragraph>Neonates, especially premature infants with low birth weight, are at increased risk of developing hypo- or hyperglycemia and therefore need close monitoring during treatment with intravenous glucose solutions to ensure adequate glycemic control in order to avoid potential long-term adverse effects. Closely monitor plasma electrolyte concentrations in pediatric patients who may have impaired ability to regulate fluids and electrolytes. In very low birth weight infants, excessive or rapid administration of 5% Dextrose and Electrolyte No. 48 Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) may result in increased serum osmolality and risk of intracerebral hemorrhage.</paragraph>
                        <paragraph>Children (including neonates and older children) are at increased risk of developing hyponatremia as well as for developing hyponatremic encephalopathy.</paragraph>
                        <paragraph>Lactate-containing solutions should be administered with particular caution to neonates and infants less than 12 months of age.  Administration of a lactate-containing intravenous solution to neonates and infants should take into account that the liver and kidneys are still maturing during the first year of life, which also affects the biotransformation and renal excretion of lactate.</paragraph>
                     </text>
                     <effectiveTime value="20200213"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_9f22298f-cbd5-445c-9833-9058eb10943e">
                     <id root="da6340aa-aff3-4eae-8091-5ebeec4593b0"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>Geriatric Use </title>
                     <text>
                        <paragraph>Geriatric patients are at increased risk of developing electrolyte imbalances. 5% Dextrose and Electrolyte No. 48 Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Therefore, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. Consider monitoring renal function in elderly patients.</paragraph>
                     </text>
                     <effectiveTime value="20200213"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_9f60cdc1-3828-4d4c-892a-fc4d1d1fd878">
                     <id root="132a9950-e377-4eba-87ac-32d5843bbb0e"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>Carcinogenesis, Mutagenesis, Impairment of Fertility </title>
                     <text>
                        <paragraph>Studies with 5% Dextrose and Electrolyte No. 48 Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) have not been performed to evaluate carcinogenic potential, mutagenic potential, or effects on fertility.</paragraph>
                     </text>
                     <effectiveTime value="20200213"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_fa5594b5-2fdd-4e61-8925-a162f8819dd0">
                     <id root="4efaec54-c2ff-4a14-afd3-db9202f84f80"/>
                     <code code="34080-2" codeSystem="2.16.840.1.113883.6.1" displayName="NURSING MOTHERS SECTION"/>
                     <title>Nursing Mothers </title>
                     <text>
                        <paragraph>It is not known whether this drug is excreted in human milk.  Because many drugs are excreted in human milk, caution should be exercised when 5% Dextrose and Electrolyte No. 48 Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) is administered to a nursing mother.</paragraph>
                     </text>
                     <effectiveTime value="20200213"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="i4i_adverse_effects_id_inv-06affc8f-d649-475a-9fe6-f9b8229384b5">
               <id root="4751f75a-3363-4634-958f-3c86fce880bc"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>ADVERSE REACTIONS</title>
               <effectiveTime value="20200213"/>
               <component>
                  <section ID="ID_8b47031d-642b-42a3-82e3-844351e6aa7c">
                     <id root="6ebeb377-66f5-45e5-a208-dd30410dc4a0"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Post-marketing Adverse Reactions </title>
                     <text>
                        <paragraph>The following adverse reactions associated with the use of 5% Dextrose and Electrolyte No. 48 Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) were identified in clinical trials or post marketing reports. Because post marketing reactions were reported voluntarily from a population of uncertain size, it is not always possible to estimate their frequency, reliably, or to establish a causal relationship to drug exposure:</paragraph>
                        <paragraph>
                           <content styleCode="italics">Hypersensitivity and Infusion Reactions:</content> palpitations, feeling abnormal, piloerection, edema peripheral, hypotension, dyspnea, wheezing, urticaria, cold sweet, tachycardia, chest pain, chest discomfort, respiratory rate increased, flushing, hyperemia, asthenia, pyrexia, chills.</paragraph>
                        <paragraph>
                           <content styleCode="italics">General Disorders and Administration Site Conditions</content>:  infusion site pain, burning sensation, febrile response, infection at the site of injection, venous thrombosis or phlebitis extending from site of injection, extravasation and hypervolemia.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Metabolism and nutrition disorders</content>: hyperkalemia, hyperglycemia, hyponatremia.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Nervous System Disorders</content>: hyponatremic encephalopathy.</paragraph>
                        <paragraph>If an adverse reaction does occur, discontinue the infusion, evaluate the patient, institute appropriate therapeutic countermeasures, and save the remainder of the fluid for examination if deemed necessary.</paragraph>
                     </text>
                     <effectiveTime value="20200213"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_db553e0b-62e0-47af-8af3-7f806f07c1e6">
                     <id root="c44692b0-57b6-4374-a669-b21805123cc9"/>
                     <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
                     <title>Overdose </title>
                     <text>
                        <paragraph>Excessive administration of 5% Dextrose and Electrolyte No. 48 Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) can cause:</paragraph>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>fluid overload with a risk of edema (peripheral and/or pulmonary), particularly when renal sodium excretion is impaired. </item>
                           <item>
                              <caption>•</caption>hyperglycemia, hyperosmolarity, and osmotic diuresis, dehydration and electrolyte loss.</item>
                           <item>
                              <caption>•</caption>hypernatremia and hyperkalemia, especially in patients with severe renal impairment. </item>
                           <item>
                              <caption>•</caption>hypermagnesemia.  </item>
                           <item>
                              <caption>•</caption>metabolic alkalosis with or without hypokalemia and decreased ionized serum calcium and magnesium concentrations. </item>
                           <item>
                              <caption>•</caption>Hyperphosphatemia, hypocalcemia, and hypomagnesemia. See <content styleCode="bold">
                                 <linkHtml href="#i4i_warnings_id_inv-ede11157-af5e-407c-8086-46b984950519">WARNINGS</linkHtml>
                              </content>
                              <content styleCode="bold"/>
                           </item>
                        </list>
                        <paragraph>When assessing an overdose, any additives in the solution must also be considered. </paragraph>
                        <paragraph>The effects of an overdose may require immediate medical attention and treatment. </paragraph>
                        <paragraph>Interventions include discontinuation of 5% Dextrose and Electrolyte No. 48 Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP), dose reduction, and other measures as indicated for the specific clinical constellation (e.g., monitoring of fluid balance, electrolyte concentrations and acid base balance).</paragraph>
                     </text>
                     <effectiveTime value="20200213"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="i4i_dosage_admin_id_inv-830fb45a-a4d4-4878-833b-3d20831f45fc">
               <id root="5effcdda-3bcd-422c-bae9-60f1c69c9ce4"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>DOSAGE AND ADMINISTRATION</title>
               <text>
                  <paragraph>
                     <content styleCode="underline">Important Administration Instructions </content>
                  </paragraph>
                  <list listType="unordered">
                     <item>
                        <caption>•</caption>5% Dextrose and Electrolyte No. 48 Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) is intended for intravenous administration using sterile equipment. </item>
                     <item>
                        <caption>•</caption>Do not connect flexible plastic containers in series in order to avoid air embolism due to possible residual air contained in the primary container. </item>
                     <item>
                        <caption>•</caption>Set the vent to the closed position on a vented intravenous administration set to prevent air embolism. </item>
                     <item>
                        <caption>•</caption>Use a dedicated line without any connections to avoid air embolism. </item>
                     <item>
                        <caption>•</caption>Do not pressurize intravenous solutions contained in flexible plastic containers to increase flow rates in order to avoid air embolism due to incomplete evacuation of residual air in the container. </item>
                     <item>
                        <caption>•</caption>Prior to infusion, visually inspect the solution for particulate matter and discoloration. The solution should be clear and there should be no precipitates. Do not administer unless solution is clear, and container is undamaged. </item>
                     <item>
                        <caption>•</caption>Do not administer 5% Dextrose and Electrolyte No. 48 Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) simultaneously with blood through the same administration set because of the possibility of pseudoagglutination or hemolysis.</item>
                  </list>
                  <paragraph>
                     <content styleCode="underline">Dosing Information</content>
                  </paragraph>
                  <paragraph>The choice of product, dosage, volume, rate, and duration of administration is dependent upon the age, weight and clinical condition of the patient and concomitant therapy, and administration should be determined by a physician experienced in intravenous fluid therapy.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Introduction of Additives </content>
                  </paragraph>
                  <paragraph>Additives may be incompatible. </paragraph>
                  <paragraph>Evaluate all additions to the plastic container for compatibility and stability of the resulting preparation. Consult with a pharmacist, if available. </paragraph>
                  <paragraph>If, in the informed judgment of the physician, it is deemed advisable to introduce additives, use aseptic technique. Mix thoroughly when additives have been introduced. After addition, if there is a discoloration and/or the appearance of precipitates, insoluble complexes or crystals, do not use. Do not store solutions containing additives. Discard any unused portion.</paragraph>
               </text>
               <effectiveTime value="20200213"/>
            </section>
         </component>
         <component>
            <section ID="i4i_how_supplied_id_inv-fbfc9b19-2ac0-49c8-8608-60412e75b161">
               <id root="b7e5479e-41ba-44c1-a3e9-da1f94dfaec8"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>HOW SUPPLIED</title>
               <text>
                  <paragraph>5% Dextrose and Electrolyte No. 48 Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) in VIAFLEX plastic containers is available as shown below:</paragraph>
                  <table styleCode="Noautorules" width="100%">
                     <col width="33%"/>
                     <col width="33%"/>
                     <col width="33%"/>
                     <tbody>
                        <tr>
                           <td align="center" valign="top">
                              <paragraph>
                                 <content styleCode="underline">Code</content>
                              </paragraph>
                           </td>
                           <td align="center" valign="top">
                              <paragraph>
                                 <content styleCode="underline">Size (mL)</content>
                              </paragraph>
                           </td>
                           <td align="center" valign="top">
                              <paragraph>
                                 <content styleCode="underline">NDC</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" valign="top">
                              <paragraph>2B2103 </paragraph>
                           </td>
                           <td align="center" valign="top">
                              <paragraph> 500 </paragraph>
                           </td>
                           <td align="center" valign="top">
                              <paragraph> NDC 0338-0143-03 </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td valign="top"/>
                           <td valign="top"/>
                           <td valign="top"/>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>Exposure of pharmaceutical products to heat should be minimized. Avoid excessive heat. It is recommended the product be stored at room temperature (25°C); brief exposure up to 40°C does not adversely affect the product.</paragraph>
               </text>
               <effectiveTime value="20200213"/>
            </section>
         </component>
         <component>
            <section ID="i4i_section_id_inv-1c0d2891-5d34-4b70-af2e-d35a0c77b79f">
               <id root="af30bb8d-2613-40fb-9bb9-db0422776c79"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <title>DIRECTIONS FOR USE OF VIAFLEX PLASTIC CONTAINERS</title>
               <text>
                  <paragraph>For Information on Risk of Air Embolism – see <linkHtml href="#i4i_dosage_admin_id_inv-830fb45a-a4d4-4878-833b-3d20831f45fc">DOSAGE AND ADMINISTRATION</linkHtml>
                  </paragraph>
               </text>
               <effectiveTime value="20200213"/>
               <component>
                  <section ID="ID_68D21AEF-20B5-427C-B6EB-285014BA1D76">
                     <id root="137fb7ef-535c-41c0-af6e-426136d89b72"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>To Open</title>
                     <text>
                        <paragraph>Tear overwrap down side at slit and remove solution container. Visually inspect the container. If the outlet port protector is damaged, detached, or not present, discard container as solution path sterility may be impaired. Some opacity of the plastic due to moisture absorption during the sterilization process may be observed. This is normal and does not affect the solution quality or safety. The opacity will diminish gradually. Check for minute leaks by squeezing inner bag firmly. If leaks are found, discard solution as sterility may be impaired. If supplemental medication is desired, follow directions below.</paragraph>
                     </text>
                     <effectiveTime value="20200213"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_3ED44426-73EA-4CB0-B09D-D6935A14569B">
                     <id root="089de792-f343-4e4d-80d7-9f34fb718609"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Preparation for Administration</title>
                     <text>
                        <list listType="ordered">
                           <item>
                              <caption>1.</caption>Suspend container from eyelet support.</item>
                           <item>
                              <caption>2.</caption>Remove port protector from outlet port at bottom of container.</item>
                           <item>
                              <caption>3.</caption>Attach administration set. Refer to complete directions accompanying set.</item>
                        </list>
                     </text>
                     <effectiveTime value="20200213"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_F7D35A28-FFAD-4ECE-801B-0474F99C625B">
                     <id root="2cc870c4-7b45-4b6d-9d25-4b53f8f18b5d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>To Add Medication</title>
                     <text>
                        <paragraph>
                           <content styleCode="bold">Warning:</content> Additives may be incompatible.</paragraph>
                     </text>
                     <effectiveTime value="20200213"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_EAF34AA7-5296-4562-8BF3-CC839033A947">
                     <id root="d6730614-2029-4248-91dc-2302f7917196"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>To add medication before solution administration</title>
                     <text>
                        <list listType="ordered">
                           <item>
                              <caption>1.</caption>Prepare medication site.</item>
                           <item>
                              <caption>2.</caption>Using syringe with 19 to 22 gauge needle, puncture resealable medication port and inject.</item>
                           <item>
                              <caption>3.</caption>Mix solution and medication thoroughly. For high density medication such as potassium chloride, squeeze ports while ports are upright and mix thoroughly.</item>
                        </list>
                     </text>
                     <effectiveTime value="20200213"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_83A28C59-0C29-44B6-A20E-1C333623D70E">
                     <id root="bbd75964-8d03-41de-b571-e14b4ff099c5"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>To add medication during solution administration</title>
                     <text>
                        <list listType="ordered">
                           <item>
                              <caption>1.</caption>Close clamp on the set.</item>
                           <item>
                              <caption>2.</caption>Prepare medication site.</item>
                           <item>
                              <caption>3.</caption>Using syringe with 19 to 22 gauge needle, puncture resealable medication port and inject.</item>
                           <item>
                              <caption>4.</caption>Remove container from IV pole and/or turn to an upright position.</item>
                           <item>
                              <caption>5.</caption>Evacuate both ports by squeezing them while container is in the upright position.</item>
                           <item>
                              <caption>6.</caption>Mix solution and medication thoroughly.</item>
                           <item>
                              <caption>7.</caption>Return container to in use position and continue administration.</item>
                        </list>
                     </text>
                     <effectiveTime value="20200213"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="i4i_section_id_724b0020-0f1c-416b-b1c7-dc4f3b5bb401">
               <id root="5c2cc954-677f-4c7a-9a08-a780f6df2c02"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">Baxter Healthcare Corporation</content>
                     <br/>Deerfield, IL 60015 USA<br/>Printed in USA</paragraph>
                  <paragraph>07-19-00-1751</paragraph>
                  <paragraph>Rev. February 2020</paragraph>
                  <paragraph>Baxter, VIAFLEX and PL 146 are trademarks of Baxter International Inc.</paragraph>
               </text>
               <effectiveTime value="20200213"/>
            </section>
         </component>
         <component>
            <section ID="i4i_Principal_display_panel_id_f4c23646-820b-481d-a2af-9c10d8db7819">
               <id root="7f507c9e-a658-42dd-8a7a-9cc4d06d32f8"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - PACKAGING LABELING</title>
               <text>
                  <renderMultiMedia ID="id400" referencedObject="id_8c82958a-8f1c-4e4d-b8e4-a53d40680d0b">
                     <caption>Container Label </caption>
                  </renderMultiMedia>
                  <paragraph>Container Label </paragraph>
                  <paragraph>Container Label </paragraph>
                  <paragraph>
                     <content styleCode="bold">LOT</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">EXP</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">2B2103</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">NDC 0338-0143-03</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">5% Dextrose</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">and Electrolyte</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">No. 48 Injection</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">(Multiple Electrolytes and Dextrose</content>
                     <br/>
                     <content styleCode="bold">Injection Type 1 USP)</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">500mL</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">500 mL</content>
                  </paragraph>
                  <paragraph>Each 100 mL contains 5 g Dextrose Hydrous USP</paragraph>
                  <paragraph>260 mg Sodium Lactate 141 mg Potassium Chloride USP</paragraph>
                  <paragraph>31 mg Magnesium Chloride USP 20 mg Monobasic</paragraph>
                  <paragraph>Potassium Phosphate NF 12 mg Sodium Chloride USP pH</paragraph>
                  <paragraph>5.0 (4.0 to 6.5) mEq/L Sodium 25 Potassium 20</paragraph>
                  <paragraph>Magnesium 3 Chloride 24 Lactate 23 Phosphate(as</paragraph>
                  <paragraph>HPO<sub>4</sub>
                     <sup>=</sup>) 3 Osmolarity 348 mOsmol/L (calc) Sterile</paragraph>
                  <paragraph>Nonpyrogenic Single dose container <content styleCode="bold">Not for use i</content>n<content styleCode="bold"> the</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">treatme</content>n<content styleCode="bold">t of lactic acidosis </content>Additives may be incompatible</paragraph>
                  <paragraph>Consult with pharmacist if available When introducing</paragraph>
                  <paragraph>additives use aseptic technique Mix thoroughly Do not</paragraph>
                  <paragraph>store Dosage Intravenously as directed by a physician See</paragraph>
                  <paragraph>directions Cautions Squeeze and inspect inner bag which</paragraph>
                  <paragraph>maintains product sterility Discard if leaks are found</paragraph>
                  <paragraph>Must not be used in series connections Do not administer</paragraph>
                  <paragraph>simultaneously with blood Do not use unless solution is</paragraph>
                  <paragraph>clear Rx Only Store unit in moisture barrier overwrap at</paragraph>
                  <paragraph>room temperature (25ºC/77ºF) until ready to use</paragraph>
                  <paragraph>Avoid excessive heat insert</paragraph>
                  <paragraph>VIAFLEX container PL 146 plastic</paragraph>
                  <paragraph>BAXTER VIAFELX and PL 146 are trademarks of</paragraph>
                  <paragraph>Baxter International Inc</paragraph>
                  <paragraph>For product information <content styleCode="bold">1-800-933-0303</content>
                  </paragraph>
                  <paragraph>Baxter Logo</paragraph>
                  <paragraph>Baxter Healthcare Corporation</paragraph>
                  <paragraph>Deerfield, IL 60015 USA</paragraph>
                  <paragraph>Made in USA</paragraph>
               </text>
               <effectiveTime value="20200213"/>
               <component>
                  <observationMedia ID="id_8c82958a-8f1c-4e4d-b8e4-a53d40680d0b">
                     <text>5% Dextrose and Electrolyte Representative Container label</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="image-02.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>